ETHIZIA
ETHICON, Inc. · Decision date Dec 15, 2025
What did the FDA approve?
FDA records P240035 as an original PMA application. The recorded decision is approval, dated Dec 15, 2025.
FDA approval order statement
Approval for ETHIZIA indicated for use in adult patients with a body weight of greater than or equal to 25kg as an adjunct to hemostasis in open liver surgery for minimal, mild, or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Dec 15, 2025
Regulatory record facts
- Identifier
- P240035
- Regulatory pathway
- Premarket approval application
- Applicant
- ETHICON, Inc.
- Product code
- SGV
- Decision code
- APPR
- Decision date
- Dec 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen with polymeric additives.
- Applicant
- ETHICON, Inc.
- Product code
- SGV
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240035 received
Application receipt date recorded by FDA.
P240035 · FDA decision
APPR
P240035/S001 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S003 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S006 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S005 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S002 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S004 · Related supplement
ETHIZIA Hemostatic Patch
Timeline entries are records held by MedtechLedger for P240035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ETHIZIA Hemostatic PatchP240035/S001 | ETHICON, Inc. | PMA supplement | Jan 22, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S003 | ETHICON, Inc. | PMA supplement | Jan 28, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S006 | ETHICON, Inc. | PMA supplement | Feb 24, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S005 | ETHICON, Inc. | PMA supplement | Feb 26, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S002 | ETHICON, Inc. | PMA supplement | Jun 25, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S004 | ETHICON, Inc. | PMA supplement | Aug 27, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ETHICON, Inc.
- Headquarters
- Not reported
- Brand website
- ethicon.com
- FDA applicant address
- 1000 Rte. 202, Raritan, NJ, 08869
Sources and methodology
- Original FDA record: P240035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records